MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jad.2026.122015

Медицинская библиотека · Journal of affective disorders · 2026

Effect of continuation treatment on health-related quality of life in remitted psychotic depression.

Bendel Ryma A, Alexopoulos George S, Marino Patricia, Meyers Barnett S, Mulsant Benoit H, Neufeld Nicholas H, Rothschild Anthony J, Voineskos Aristotle N, Whyte Ellen M, Flint Alastair J, Bingham Kathleen S, STOP-PD II Study Group

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Continuation treatment with sertraline plus olanzapine is associated with lower risk of relapse of remitted psychotic depression than sertraline plus placebo. We examined the effect of continuation pharmacotherapy on health-related quality of life (HRQOL) in remitted psychotic depression.

METHODS

One hundred and twenty-six men and women, aged 18 to 85 years, who had achieved sustained remission of psychotic depression with open-label treatment with sertraline plus olanzapine were randomized to continue sertraline plus either olanzapine or placebo. HRQOL was measured with the 36-item Short Form Health Survey (SF-36) at randomization baseline and study termination. The primary outcome was change in each of the eight SF-36 domains. Linear regression examined the relationship between randomized treatment and change in SF-36 domain scores.

RESULTS

Sertraline plus olanzapine was associated with better outcomes in the Role Emotional (RE) and Mental Health (MH) domains than sertraline plus placebo. Relapse was associated with marked decline in both RE and MH scores. RE and MH scores at study termination were more than two standard deviations below the population mean in approximately one quarter of participants in the sertraline plus placebo group.

CONCLUSIONS

In individuals with remitted psychotic depression, continuation treatment with sertraline plus olanzapine was associated with better outcomes in HRQOL domains directly relevant to mental health than treatment with sertraline plus placebo. These findings suggest that the benefit of sertraline plus olanzapine in preventing relapse of psychotic depression is associated with benefit in HRQOL.

Для цитирования: Bendel Ryma A, Alexopoulos George S, Marino Patricia, Meyers Barnett S, Mulsant Benoit H, Neufeld Nicholas H, Rothschild Anthony J, Voineskos Aristotle N, Whyte Ellen M, Flint Alastair J, Bingham Kathleen S, STOP-PD II Study Group. Effect of continuation treatment on health-related quality of life in remitted psychotic depression.. Journal of affective disorders. 2026. DOI: 10.1016/j.jad.2026.122015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.